Crown Equity Holdings Inc. (CRWE)
CRWE ‘s goal is to accelerate the success of the company, by refocusing on prior endeavors to deliver value for its stockholders in both the near and long term.
CRWE has refocused its efforts and direction to an online business-to-business (B2B) marketplace platform for manufacturers and small to large businesses on a global basis to sell and acquire various types of merchandise.
Strategic plans are also being developed for CRWE ’s online video-sharing and VoIP communication projects to improve the potential future growth for the company.
According to the Interactive Advertising Bureau (IAB) Internet Advertising Revenue Report, prepared by auditor PricewaterhouseCoopers:
- Internet advertising revenue reached $20.1 billion in the first half of the year, up 18.2% over the first half of last year.
- In the second quarter, Internet ad revenue totaled $10.3 billion, up 18.4% over the same period last year.
- Revenue from mobile advertising soared to $3.0 billion in the first half, up 145.0% over the first half of last year. Online video spending totaled $1.3 billion in the first half, up 24.0%.
CRWE last trade was at $0.005, with a volume of 1,000,000 shares traded so far
Together with its digital network of Websites, CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .
*************
Antares Pharma, Inc. (Nasdaq:ATRS)
Shares of ATRS surged on Monday's trading session after the company reported the approval of OTREXUP(TM) (methotrexate) injection by the FDA.
OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
OTREXUP is indicated for adults with severe active rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents, or children with active polyarticular juvenile idiopathic arthritis. The FDA also approved adult use of OTREXUP for symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy.
In 2012, approximately six million prescriptions were written across all dosage forms of methotrexate in the U.S. to treat patients for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriasis, the same indications for which OTREXUP has been approved. Methotrexate treatment is usually initiated with oral tablets, however; many patients experience an inadequate response for reasons of efficacy or tolerability.
Rheumatoid arthritis is a chronic, systemic autoimmune disease characterized by pain and inflammation of the joints. Polyarticular juvenile idiopathic arthritis is a subgroup of juvenile idiopathic arthritis in which five or more joints are impacted in children within the first six months after disease onset. Psoriasis is a chronic autoimmune skin disease that most commonly appears as raised, red patches with a white buildup of dead skin cells.
Human study data submitted to the FDA demonstrated increased bioavailability of subcutaneous methotrexate compared to oral methotrexate at every dose.
ATRS stock is trading for about $4.73, up $0.20 or 4.42%, with over 8,907,000 shares traded so far.
ATRS focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines.
More about Antares Pharma, Inc. (Nasdaq:ATRS) at www.antarespharma.com
********************************
Full Disclaimer at www.pennyomega.com/disclaimer
